moxifloxacin has been researched along with zanamivir in 4 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (zanamivir) | Trials (zanamivir) | Recent Studies (post-2010) (zanamivir) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,168 | 85 | 546 |
| Protein | Taxonomy | moxifloxacin (IC50) | zanamivir (IC50) |
|---|---|---|---|
| Chain A, Neuraminidase | Influenza B virus (STRAIN B/BEIJING/1/87) | 0.004 | |
| Chain A, Neuraminidase | Influenza B virus (STRAIN B/BEIJING/1/87) | 0.004 | |
| Chain A, Neuraminidase | Influenza A virus | 0.004 | |
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | 0.0054 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.0364 | |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | 0.0027 | |
| Neuraminidase | Influenza A virus (A/Brisbane/59/2007(H1N1)) | 0.0276 | |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 0.0043 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.0017 | |
| Neuraminidase | Influenza A virus (A/Memphis/1/1971(H3N2)) | 0.0147 | |
| Neuraminidase | Influenza B virus (B/Lee/1940) | 0.0809 | |
| Neuraminidase | Influenza A virus (A/udorn/1972(H3N2)) | 0.0154 | |
| Acyl-CoA desaturase 1 | Mus musculus (house mouse) | 0.001 | |
| Neuraminidase | Influenza B virus (STRAIN B/VICTORIA/3/85) | 0.0045 | |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | 0.0077 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0074 | |
| Neuraminidase | Influenza A virus (A/duck/Ukraine/1/1963(H3N8)) | 0.0074 | |
| Neuraminidase | Influenza A virus (A/RI/5+/1957(H2N2)) | 1.4 | |
| Neuraminidase | Influenza A virus (A/udorn/1972(H3N2)) | 0.0229 | |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | 0.0007 | |
| Neuraminidase | Influenza B virus (B/Perth/211/2001) | 0.0882 | |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | 0.0024 | |
| Neuraminidase | Influenza A virus (A/Singapore/1/1957(H2N2)) | 0.007 | |
| Neuraminidase | Influenza A virus (A/budgerigar/Hokkaido/1/1977(H4N6)) | 0.0228 | |
| Neuraminidase | Influenza A virus (A/Aichi/2/1968(H3N2)) | 0.0027 | |
| Integrase | Human immunodeficiency virus 1 | 0.0025 | |
| Sialidase-3 | Homo sapiens (human) | 5.6617 | |
| Sialidase-2 | Homo sapiens (human) | 6.7333 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Gan, J; Gould, E; Lou, Y; Patel, P; Peppercorn, A; Piscitelli, SC; Weller, S | 1 |
1 trial(s) available for moxifloxacin and zanamivir
| Article | Year |
|---|---|
Effect of intravenous zanamivir on cardiac repolarization.
Topics: Administration, Oral; Adult; Antiviral Agents; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Infusions, Intravenous; Long QT Syndrome; Male; Moxifloxacin; Quinolines; Time Factors; Young Adult; Zanamivir | 2013 |
3 other study(ies) available for moxifloxacin and zanamivir
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |